Dose-Limiting Toxicities: Theseus Pharma Terminates THE-630 Study For Gastrointestinal Cancer
Portfolio Pulse from Vandana Singh
Theseus Pharmaceuticals Inc (NASDAQ:THRX) has decided to terminate the development of THE-630 for gastrointestinal stromal tumors (GIST) due to dose-limiting toxicities. The company will discontinue enrollment in the ongoing phase 1/2 study. The decision was made after observing hand-foot skin reactions in patients. The company is now prioritizing THE-349 for EGFR mutant non-small cell lung cancer and announced a new program targeting KIT for patients with early-line GIST. Following the news, THRX shares are down 65.50%.
July 14, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Theseus Pharmaceuticals' decision to terminate the development of THE-630 for GIST due to dose-limiting toxicities has led to a significant drop in its share price.
The termination of the development of a drug due to dose-limiting toxicities is a significant setback for a pharmaceutical company. This news directly impacts Theseus Pharmaceuticals as it indicates a failure in their drug development process, which can lead to a loss of potential revenue from the drug. This has resulted in a significant drop in the company's share price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100